Elebsiran is an antisense rnai oligonucleotide commercialized by Brii Biosciences, with a leading Phase II program in Hepatitis B. According to Globaldata, it is involved in 15 clinical trials, of which 3 were completed, 8 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Elebsiran’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Elebsiran is expected to reach an annual total of $30 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Elebsiran Overview

Elebsiran (VIR-2218) is under development for the treatment of hepatitis B and D virus infections. It is administered through subcutaneous route and acts by targeting hepatitis B virus (HBV) genome including HBsAg. It is a siRNA therapeutic developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology.

Brii Biosciences Overview

Brii Biosciences is a biotechnology company that develops and commercializes medicines to treat central nervous systems and infectious disease. It is investigating BRII-835 (VIR-2218) and BRII-179 (VBI-2601) against Hepatitis B virus; BRII-658 targeting multidrug-resistant TB (MDR-TB) mycobacteria; and BRII-636 (QPX-7728), BRII-672 (QPX-7831) and BRII-693 (QPX-9003) to treat infections caused due to multidrug-resistant gram-negative bacteria (MDR-GNB). The company is also evaluating BRII-732 and BRII-778 against human immunodeficiency virus (HIV); BRII-196 and BRII-198 targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); BRII-296 for paranoid personality disorder and major depressive disorder (MDD). The company has operations in China and the US. Brii Biosciences is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY51.6 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was CNY488.9 million in FY2022, compared to an operating loss of CNY4,189.9 million in FY2021. The net loss of the company was CNY484.3 million in FY2022, compared to a net loss of CNY4,163.9 million in FY2021.

For a complete picture of Elebsiran’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.